Company intelligence / Profile preview

DMK Pharmaceuticals Corporation

San Diego, California, United Statesfda.gov ↗

Ownership: Private
Employees: ~18
Development stage: Commercial

Overview

The company has FDA-approved products including ZIMHI (naloxone) for opioid overdose and SYMJEPI (epinephrine) for allergic reactions. They are also developing Tempol for COVID-19 treatment with over 100 subjects enrolled in Phase 2/3 trials as of February 2022, and DPI-125 for opioid use disorder.

Therapeutic areas: PulmonologyPsychiatryImmunologyNeurologyInfectious Diseases
Modalities: Small moleculesinjectable formulations
Industry: Biotech

Drug pipeline

4 assets

tempol

3 more assets in the full pipeline.

Request access →

Partnerships

NIH (grant for alcohol use disorder treatment development)

Beyond the preview

Go deeper on DMK Pharmaceuticals Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DMK Pharmaceuticals Corporation.

Explore the full profile